

Mitsubishi Tanabe Pharma to remain a component of Nikkei 300 and Nikkei 500 for now

Mitsubishi Tanabe Pharma Corp. (4508) will remain a component of the Nikkei Stock Index 300 and Nikkei 500 Stock Average for the time being, responding to its designation to “Stock under supervision” (i.e. Kanri Meigara) by the Tokyo Stock Exchange on November 18, 2019.

A decision will be made on whether to replace the stock as one of the Nikkei 300 and Nikkei 500 Average based on a comprehensive assessment of the situation, including its takeover bid.

News Tag : Nikkei300, Nikkei500, ComponentChange

Index Business Office, Nikkei Inc.
indexes.nikkei.co.jp